Chiesi Farmaceutici S.p.a.

Genentech, Inc.

Convergence Pharmaceuticals Limited

Andrew Peter Cridland

Christopher Hurley

Monique Bodil Van Niel

Andrew Stephen Robert Jennings

Lilian Alcaraz

Terry Aaron Panchal

Elisabetta Armani

Nicholas Charles Ray

Stuart Ward

Benjamin Fauber

Jonathan Killen

Jag Paul Heer

Paul John Beswick

Robert James Gleave

Sadie Vile

Neville Hubert Nicholson

Lee William Page

Alister Campbell

James John Crawford

Emanuela Gancia

Alberto Gobbi

Sarah Bronner

Paul Winship

Huifen Chen

Wendy Lee

Matthew Volgraf

Elisia Villemure

David Norton

Daniel Shore

Jason R Zbieg

David Nigel Hurst

Aijun Lu

Robin Larouche-Gauthier

Francis Beaumier

Olivier Rene

Baihua Hu

Patrick Cyr

Martin Dery

Robert Maxey

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, p, q A, B, R, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Pyridazine derivatives as RORc modulators

The invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as respiratory disorders or pain.

Oxadiazolones as transient receptor potential channel inhibitors

Compounds of formula I: or pharmaceutical salts thereof,wherein m, n, A, R1, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Compounds of formula I: or pharmaceutical salts thereof,

Compounds of the formula I: or a pharmaceutical salt thereof,wherein X, Ar, R1, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.

Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38&#x2014;MAP kinase inhibitors

Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R, W, A, Y and Rare as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Kinase inhibitors

Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Compounds of formula (I): wherein R, W, A, Y, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Growing community of inventors

Cambridge, United Kingdom

Andrew Peter Cridland